Topical oral dosage forms containing bismuth compounds
AssigneeJosman Laboratories, Inc.
InventorsNarayan K. Athanikar, Scott A. Gubler
Life of this patent
Estimating the term…
Abstract
Topical oral dosage forms containing bismuth compounds are described, which are useful for treating H. pylori and other bacterial infections that cause gastrointestinal disorders and halitosis, as well as for treating ocular and dermal wounds. Methods of employing topical oral dosage forms for treating bacterial infections that cause gastrointestinal disorders and halitosis, and for treating ocular and dermal wounds, are also described.
Claims24
A topical oral dosage form comprising a pharmaceutically active agent effective against bacteria in an oral cavity which causes halitosis, wherein the pharmaceutically active agent comprises a bismuth compound, and wherein the topical oral dosage form provides controlled release of the bismuth compound into saliva in the oral cavity for at least 5 minutes in a concentration in the saliva of at least 2 μg/mL.
A topical oral dosage form selected from the group consisting of chewing gum, chewable tablets, lozenges, dental paints, viscous gels, dental implants, polymer film adhesives, troches, toothpastes, gargling gels, mouth rinses, and combinations thereof, wherein the topical oral dosage form comprises an effective amount of a pharmaceutically active anti-bacterial agent consisting essentially of a bismuth compound selected from the group consisting of colloidal bismuth subcitrate, bismuth subcitrate, bismuth citrate, bismuth salicylate, bismuth subsalicylate, bismuth subnitrate, bismuth subcarbonate, bismuth tartrate, bismuth subgallate, tripotassium dicitrato bismuthate, bismuth aluminate, bismuth polysulfates, bismuth polyhydroxy compounds, alpha-D-glucopyranoside bismuth complex, beta-D-fructofuranosyl-oktakis (hydrogen sulfate) bismuth complex, L-dihydro ascorbyl-tetrakis (hydrogen sulfate) bismuth complex, bismuth ascorbyl sulfate, bismuth subascorbate, bismuth sucrose sulfate, bismuth cyclodextrin sulfate, and combinations thereof, wherein the topical oral dosage form provides controlled release of the bismuth compound into the saliva in the oral cavity for at least 5 minutes in a concentration in the saliva of at least 2 μg/mL.
Dependencies are inferred from the claim text.